Literature DB >> 12191517

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

Sandra Tuyaerts1, Sofie M Noppe, Jurgen Corthals, Karine Breckpot, Carlo Heirman, Catherine De Greef, Ivan Van Riet, Kris Thielemans.   

Abstract

There is a growing interest in using dendritic cells (DC) for vaccine approaches in the treatment of cancer and infectious diseases. This requires a reproducible method for the generation of large numbers of DC in a closed culture system suitable for clinical use and conforming to the current guidelines of good manufacturing practices. We designed a system in which the DC were generated in a closed system from adherent monocytes using Cell Factories (DC-CF). Monocytes were enriched from apheresis products by adherence and then cultured in the presence of AB serum or autologous plasma and GM-CSF and IL-4 for 6 days. The DC generated in Cell Factories were extensively compared to research-grade DC generated in conventional tissue culture flasks (DC-TCF). At day 6, the immature DC were harvested and the yield, the viability, the immunophenotype and the functional characteristics of the DC were compared.DC-CF and DC-TCF showed similar viability and purity and scored equally when tested for stability, dextran and latex bead uptake, in MLR and in the activation of influenza-specific memory cells after electroporation with influenza matrix protein 1 (IMP1) mRNA. These data indicated that large numbers of functional clinical-grade DC could be generated from adherent cells in a closed system using Cell Factories.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191517     DOI: 10.1016/s0022-1759(02)00099-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  20 in total

Review 1.  Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells.

Authors:  Steven De Vleeschouwer; Stefaan W Van Gool; Frank Van Calenbergh
Journal:  Childs Nerv Syst       Date:  2004-09-28       Impact factor: 1.475

2.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Authors:  An M T Van Nuffel; Daphné Benteyn; Sofie Wilgenhof; Lauranne Pierret; Jurgen Corthals; Carlo Heirman; Pierre van der Bruggen; Pierre G Coulie; Bart Neyns; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

3.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 4.  Dendritic cell vaccines for brain tumors.

Authors:  Won Kim; Linda M Liau
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 5.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

6.  Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model.

Authors:  Seagal Teitz-Tennenbaum; Qiao Li; Mary A Davis; Alfred E Chang
Journal:  Clin Immunol       Date:  2008-10-08       Impact factor: 3.969

7.  Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells.

Authors:  B Movahedi; M Van de Casteele; N Caluwé; G Stangé; K Breckpot; K Thielemans; G Vreugdenhil; C Mathieu; D Pipeleers
Journal:  Diabetologia       Date:  2004-06-08       Impact factor: 10.122

8.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

Authors:  David Escors
Journal:  New J Sci       Date:  2014-01-05

Review 9.  Improving vaccine efficacy against malignant glioma.

Authors:  Erik Ladomersky; Matthew Genet; Lijie Zhai; Galina Gritsina; Kristen L Lauing; Rishi R Lulla; Jason Fangusaro; Alicia Lenzen; Priya Kumthekar; Jeffrey J Raizer; David C Binder; C David James; Derek A Wainwright
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

10.  Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.

Authors:  Frederick Arce; Karine Breckpot; Holly Stephenson; Katarzyna Karwacz; Michael R Ehrenstein; Mary Collins; David Escors
Journal:  Arthritis Rheum       Date:  2011-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.